dioxadet has been researched along with Disease Models, Animal in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belyaev, AM; Belyaeva, OA; Bespalov, VG; Gafton, GI; Guseynov, KD; Kireeva, GS; Maydin, MA; Semenov, AL; Senchik, KY; Stukov, AN | 1 |
| Belyaev, AM; Belyaeva, OA; Bespalov, VG; Gafton, GI; Guseynov, KD; Kalinin, OE; Kireeva, GS; Senchik, KY; Stukov, AN | 1 |
| Kraĭz, BO; Tret'iakov, AV | 1 |
3 other study(ies) available for dioxadet and Disease Models, Animal
| Article | Year |
|---|---|
Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Disease Models, Animal; Female; Hyperthermia, Induced; Infusions, Parenteral; Leukocyte Count; Leukocytes; Ovarian Neoplasms; Random Allocation; Rats; Rats, Wistar; Triazines | 2016 |
Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model.
Topics: Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Disease Models, Animal; Female; Hyperthermia, Induced; Infusions, Parenteral; Ovarian Neoplasms; Random Allocation; Rats; Triazines | 2016 |
[Potentiation of the antitumor activity of dioxadet by antiestrogen para-aminobenzhydrazide in a model of ovarian ascites tumor].
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Ascites; Disease Models, Animal; Drug Synergism; Female; Ovarian Neoplasms; Rats; Rats, Inbred Strains; Triazines | 1983 |